title: Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus.
abstract: The effects of GPIIb/IIIa blockade on clot retraction were studied utilizing an instrument which directly measures force produced by platelets. GPIIb/IIIa disruption by calcium chelation, and GPIIb/IIIa blockade by peptides and anti-GPIIb/IIIa antibodies were investigated. One mM EDTA suppressed ADP-induced platelet aggregation by 72% and reduced force developed at 1200 s by 33%. At 234 microM, the tetrapeptide Arg-Gly-Asp-Ser (RGDS) suppressed platelet aggregation by 74%, reduced force at 1200 s by 45% and reduced gel elastic modulus by 19%. At 10 microM, the peptide D-Arg-Gly-L-Asp-L-Try (D-RGDW) completely suppressed platelet aggregation, reduced force development by 38% and reduced gel elastic modulus by 29%. At 0.133 microM, monoclonal anti-GPIIIa antibody (AP-3) reduced force development by 74% and reduced gel modulus by 60%. Murine antiGPIIb/IIIa antibodies 10E5 and 7E3 markedly suppressed force development. At 0.133 microM, 10E5 reduced force by 89% and reduced gel modulus by 67%. At 0.053 microM, 7E3 completely stopped force development and reduced gel modulus by 46%. Platelet aggregation was blocked by 0.027 microM 7E3. Selective GPIIb blockade by antibodies did not affect force development. None of the agents studied altered fibrin structure as monitored by effects of fibrin mass/length ratios. Suppression of platelet aggregation occurred at inhibitor concentrations substantially lower than those required to suppress force development. Complete suppression of platelet aggregation did not assure inhibition of clot retraction probably due to profound platelet activation by thrombin.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Medical College of Virginia, Richmond, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Carr
authors.forename: S L
authors.initials: SL
authors.lastname: Carr
authors.forename: R R
authors.initials: RR
authors.lastname: Hantgan
authors.forename: J
authors.initials: J
authors.lastname: Braaten
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology*; D002122:Calcium Chloride / Q000494:pharmacology; D003018:Clot Retraction; D015195:Drug Design; D004492:Edetic Acid / Q000494:pharmacology; D004548:Elasticity; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005782:Gels; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000276:immunology / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D005782:Gels; D009842:Oligopeptides; D010980:Platelet Membrane Glycoproteins; C082481:arginyl-glycyl-aspartyl-tryptophan; D004492:Edetic Acid; C046617:arginyl-glycyl-aspartyl-serine; D002122:Calcium Chloride